Sobi 将 2025 年的收入预期上调至低两位数，理由是第三季度业绩强劲，欧盟对 Tryngolza 的新批准。 Sobi raised 2025 revenue outlook to low double digits, citing strong Q3 results and new EU approval for Tryngolza.

瑞典一家生物制药公司Sobi将其2025年全年收入增长前景提高到按不变汇率计算的低两位数百分比,以Q3表现强劲,收入达到77.76亿瑞典克朗,增长21%。 Sobi, a Swedish biopharma company, raised its 2025 full-year revenue growth outlook to a low double-digit percentage at constant exchange rates, citing strong Q3 performance with SEK 7.776 billion in revenue, a 21% increase. 该公司还在研发支出减少和成本纪律降低的推动下,改进了经调整的EBITA预测到中高30年代的比值。 The company also improved its adjusted EBITA margin forecast to the mid-to-high 30s, driven by lower R&D spending and cost discipline. Altuvoct、Doptelet和Gamifant的销售促进了Q3的结果。 Q3 results were boosted by sales of Altuvoct, Doptelet, and Gamifant. Sobi将其Q3财务报告发布日期提前至2025年10月20日,并报告了对Vonjo的6,612亿瑞典克朗减值费,但不影响现金流动。 Sobi advanced its Q3 financial report release to October 20, 2025, and reported a SEK 6.612 billion impairment charge for Vonjo, which did not affect cash flow. 该公司获得了Tryngolza在家族性胆小糖血症综合征的欧洲批准,并报告了严重高甘油三血症的阳性数据,预计在主要欧盟国家和英国的市场潜力超过50亿瑞典克朗. The company gained European approval for Tryngolza in familial chylomicronaemia syndrome and reported positive data for severe hypertriglyceridemia, with a projected market potential exceeding SEK 5 billion in key EU countries and the UK. 计划在2026年提交多因子血清综合症的监管文件,在美国、加拿大和中国以外的大多数市场拥有商业权利。 Regulatory filings for multifactorial chylomicronemia syndrome are planned for 2026, with commercial rights held in most markets outside the U.S., Canada, and China.